The critical role of short-chain fatty acids in health and disease : A subtle focus on cardiovascular disease-NLRP3 inflammasome-angiogenesis axis
Copyright © 2022 Elsevier Inc. All rights reserved.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 238(2022) vom: 15. Mai, Seite 109013 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2022
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Review Research Support, Non-U.S. Gov't Angiogenesis CVD NLRP3 inflammasome SCFAs Fatty Acids, Volatile Inflammasomes NLR Family, Pyrin Domain-Containing 3 Protein |
| Résumé: | Copyright © 2022 Elsevier Inc. All rights reserved. Short-chain fatty acids (SCFAs), metabolites of intestinal microorganisms, have been linked to the occurrence and development of a variety of disorders, including cardiovascular disease (CVD), which is frequently accompanied by a sustaining inflammatory response and aberrant angiogenesis. Accumulating evidence from the study emphasizes that SCFAs are closely connected with the activation of the NLRP3 inflammasome (NACHT, LRR, and PYD domains-containing protein 3) and the process of angiogenesis. This review summarizes emerging literature on the impact of SCFAs on various physiological processes, with a subtle attention on the interaction between SCFAs and CVD (especially atherosclerosis, myocardial infarction, and hypertension), SCFAs and NLRP3 inflammasome, as well as SCFAs and angiogenesis. As a result, we speculate that it is convincing that SCFAs play a mediating role in the microbiota-inflammasome-angiogenesis-CVD axis, opening up a new horizon to investigate the function or level of SCFAs as a therapeutic strategy for CVD |
|---|---|
| Description: | Date Completed 19.05.2022 Date Revised 20.05.2022 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2022.109013 |